热线电话: 021-34661275
产品分类/PRODUCT CLASSIFICATION

上海细胞库

人源细胞系| 稳转细胞系| 基因敲除株| 基因点突变细胞株| 基因过表达细胞株| 重组细胞系| 猪的细胞系| 马细胞系| 兔的细胞系| 犬的细胞系| 山羊的细胞系| 鱼的细胞系| 猴的细胞系| 仓鼠的细胞系| 狗的细胞系| 牛的细胞| 大鼠细胞系| 小鼠细胞系| 其他细胞系|

原代细胞

原代细胞| 永生化细胞|

细胞培养

血清| 无血清冻存| 细胞培养试剂盒| 普通培养基| 完全培养基| 细胞污染预防| 细胞污染清除| 细胞培养辅助试剂|

细胞服务

STR鉴定服务| ATCC代购服务|

酶联试剂盒

人ELISA试剂盒| 大鼠ELISA试剂盒| 小鼠ELISA试剂盒| 兔ELISA试剂盒| 猪ELISA试剂盒| 鱼ELISA试剂盒| 牛ELISA试剂盒| 犬ELISA试剂盒| 鸭ELISA试剂盒| 豚鼠ELISA试剂盒| 鸡ELISA试剂盒| 绵羊ELISA试剂盒| 山羊ELISA试剂盒| 仓鼠ELISA试剂盒| 植物ELISA试剂盒| 药残留类试剂盒| 其他ELISA试剂盒|

生化试剂盒

生化试剂盒| 微量法检测盒| 分光法检测盒| 胶体金检测盒|

PCR试剂盒

荧光探针PCR试剂盒| 染料荧光PCR试剂盒| 核酸扩增/纯化| 普通PCR检测试剂盒| 质粒菌种感受态|

抗体蛋白

蛋白多肽| 抗体| 免疫组化| 免疫球蛋白|

试剂耗材

标准试液| 科研试剂| 缓 冲 液| 实验耗材| 高效液相色谱对照品|

首页 > 抗体蛋白 > 抗体
FITC anti-human CD90 (Thy1) Antibody
产品名称：
FITC anti-human CD90 (Thy1) Antibody
产品类别：
抗体
产品编号：
328107
产品应用：
328107
[价格]
规格 价格 库存
25tests ￥ 1212 1

产品详情

Product Details

Verified Reactivity
Human
Reported Reactivity
African Green, Baboon, Cynomolgus, Pigtailed Macaque, Rhesus, Pig
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
HEL cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone 5E10 recognizes an epitope on Thy-1 independent of its glycosylation, but is abolished under reducing conditions.4?Additional reported (for the relevant formats) applications include: immunohistochemical staining of acetone-fixed frozen sections, immunoprecipitation1, and immunofluorescence3.

Application References

(PubMed link indicates BioLegend citation)
  1. Craig W, et al. 1993. J. Exp. Med. 177:1331. (IP)
  2. Gundlach CW 4th, et al. 2011. Bioconjug. Chem. 22:1706. (Pig Reactivity)
  3. Touboul C, et al. 2013. J. Transl. Med. 11:28. (IF)
  4. Bradley JE, et al. 2013. Lab Invest. 93:365. (Epitope)
  5. Donnenberg VS, et al. 2010. Cytometry B. Clin. Cytom. 5:287. (IHC)
Product Citations
  1. Miksiunas R, et al. 2021. Int J Mol Sci. 22:. PubMed
  2. Wu J, et al. 2022. Nat Commun. 13:676. PubMed
  3. Camerlingo R, et al. 2011. Lung Cancer. 72:23. PubMed
  4. Peng K, et al. 2020. Sci Rep. 10:18433. PubMed
  5. Yan H, et al. 2020. Adv Sci (Weinh). 7:1903516. PubMed
  6. Xin Y, et al. 2021. Stem Cell Res Ther. 49:12. PubMed
  7. Chen X, et al. 2022. Front Bioeng Biotechnol. 10:915181. PubMed
  8. Yu XX, et al. 2021. Cell Res. 31:886. PubMed
  9. Shi L, et al. 2021. Stem Cell Res Ther. 12:147. PubMed
  10. Li L, et al. 2015. Int J Pharmaceutics. 488: 1-11. PubMed
  11. Liu X, et al. 2020. Exp Ther Med. 1.258333333. PubMed
  12. Radhakrishnan S, et al. 2019. Mol Med Rep. 20:813. PubMed
  13. Guney-Esken G, et al. 2021. Stem Cell Res Ther. 12:287. PubMed
  14. Tu S, et al. 2020. Cellular Signalling. 73:109695. PubMed
  15. Vishnoi M, et al. 2018. Cancer Res. 78:5349. PubMed
  16. Huang X, et al. 2019. Oxid Med Cell Longev. 2019:1305049. PubMed
  17. Takao T, et al. 2022. STAR Protoc. 3:101786. PubMed
  18. Qin XY, et al. 2020. Cell Death Dis. 0.504166667. PubMed
  19. Hwang Y, et al. 2021. Int J Mol Sci. 22:. PubMed
  20. Dregalla RC, et al. 2021. Stem Cell Res Ther. 12:547. PubMed
  21. Nguyen MAT, et al. 2020. Immunohorizons. 0.465277778. PubMed
  22. Liu Z, et al. 2021. Molecules. 26:. PubMed
  23. Han X, et al. 2020. Int J Oral Sci. 12:10. PubMed
  24. Hanse E, et al. 2017. Oncogene. 10.1038/onc.2017.36. PubMed
  25. Sun W, et al. 2019. Exp Ther Med. 17:2199. PubMed
  26. Liu Y, et al. 2022. iScience. 25:104405. PubMed
  27. Yan K, et al. 2022. iScience. 25:104822. PubMed
  28. DAgostino S, et al. 2021. Frontiers in Oncology. 10:600980. PubMed
  29. Kinchen J et al. 2018. Cell. 175(2):372-386 . PubMed
  30. Gao P, et al. 2017. Cytotechnology. 69:751. PubMed
  31. Nguyen JT, et al. 2019. iScience. 17:190. PubMed
  32. Yu C, et al. 2020. Sci Rep. 10:14521. PubMed
  33. Duan X, et al. 2022. Cell Biosci. 12:60. PubMed
  34. Fawkner-Corbett D, et al. 2021. STAR Protoc. 2:100890. PubMed
  35. Zhang S, et al. 2021. Stem Cells Int. 6616240:2021. PubMed
  36. Yang C et al. 2019. Int J Mol Med. 43(3):1395-1405 . PubMed
  37. Tidu F, et al. 2021. iScience. 24(6):102683. PubMed
  38. Ayhan S, et al. 2021. Journal of Cell Science. 134(6):. PubMed
  39. Cai S, et al. 2022. Cell Biosci. 12:115. PubMed
  40. Noz MP, et al. 2020. Elife. 9:00. PubMed
  41. Zhang Y, et al. 2018. Stem Cells Int. 2018:7159465. PubMed
  42. Zhang Y, et al. 2019. Aging (Albany NY). 11:12641. PubMed
  43. Guney-Esken G, et al. 2021. Methods Mol Biol. 2549:23. PubMed
  44. Keshtkar S, et al. 2021. Stem Cells Int. 8857457:2020. PubMed
  45. Okamura G, et al. 2020. Int J Mol Sci. 22:00. PubMed
  46. Zhang H, et al. 2017. Oncogene. 10.1038/onc.2016.512. PubMed
  47. Sun T, et al. 2019. Haematologica. 105:661. PubMed
  48. Motedayyen H, et al. 2017. BMC Res Notes. . 10.1186/s13104-017-2880-6. PubMed
  49. Narakornsak S, et al. 2017. Acta Histochemica. 10.1016/j.acthis.2017.04.006. PubMed
  50. Xu L, et al. 2022. Int J Mol Sci. 23:. PubMed
  51. Miksiunas R, et al. 2022. Cells. 11:. PubMed
  52. Aomatsu E, et al. 2014. Sci Rep. 4:3652. PubMed
  53. Fawkner-Corbett D, et al. 2021. Cell. 184(3):810-826.e23. PubMed
  54. He Z, et al. 2020. J Exp Clin Cancer Res. 39:140. PubMed
  55. Meng Z, et al. 2013. Mol Cancer Ther. 12:2067. PubMed
  56. He H, et al. 2019. J Cell Mol Med. 23:4139. PubMed
  57. Zhu YP et al. 2018. Cell reports. 24(9):2329-2341 . PubMed
  58. Pauken CM, et al. 2021. Cancers (Basel). 13:. PubMed
  59. Vishnoi M, et al. 2019. Mol Oncol. 13(9): 1913. PubMed
  60. Putra I, et al. 2021. Transl Vis Sci Technol. 10:3. PubMed
  61. Matheni C, et al. 2021. Cell J. 23:145. PubMed
  62. Miksiunas R, et al. 2020. Int J Mol Sci. 21:00. PubMed
  63. Luzuriaga J, et al. 2020. Biomedicines. 8:00. PubMed
  64. Dinh HQ, et al. 2020. Immunity. 53(2):319-334.e6. PubMed
  65. Hong Y, et al. 2020. Aging Cell. 19:e13128. PubMed
  66. Chijimatsu R, et al. 2022. Regen Ther. 21:52. PubMed
  67. Shang W, et al. 2022. Dis Markers. 2022:7286645. PubMed
  68. Khanh VC, et al. 2021. Stem Cells Dev. 30:758. PubMed
  69. Thiel A, et al. 2015. Sci Rep. 5: 17685. PubMed
  70. Sprouse ML, et al. 2019. Int J Mol Sci. 20:8. PubMed
RRID
AB_893438 (BioLegend Cat. No. 328107) AB_893429 (BioLegend Cat. No. 328108)

Antigen Details

Structure
25-35 kD glycoprotein, Ig superfamily
Distribution

Subset of CD34+ hematopoietic stem cells, subset of fetal thymocytes, subset of fetal liver cells, fibroblast, activated endothelial cells, neurons and some leukemia cell lines

Function
Regulate hematopoiesis and neural cell growth, cell adhesion
Ligand/Receptor
β3 integrin, β2 integrin
Cell Type
Endothelial cells, Fibroblasts, Hematopoietic stem and progenitors, Leukemia, Mesenchymal Stem Cells, Neurons, Thymocytes
Biology Area
Immunology, Stem Cells
Molecular Family
CD Molecules
Antigen References

1. McKenzie JL, et al. 1981. J. Immunol. 126:843.
2. Avalos AM, et al. 2002. Biol. Res. 35:231.
3. Wetzel A, et al. 2004. J. Immunol. 172:3850.

Gene ID
7070 View all products for this Gene ID
UniProt
View information about CD90 on UniProt.org

联系我们

TEL：021-34661275 　点击拨打热线